183 related articles for article (PubMed ID: 2021551)
1. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
[TBL] [Abstract][Full Text] [Related]
2. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
Lien EA; Solheim E; Lea OA; Lundgren S; Kvinnsland S; Ueland PM
Cancer Res; 1989 Apr; 49(8):2175-83. PubMed ID: 2702659
[TBL] [Abstract][Full Text] [Related]
3. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.
Lien EA; Solheim E; Ueland PM
Cancer Res; 1991 Sep; 51(18):4837-44. PubMed ID: 1893376
[TBL] [Abstract][Full Text] [Related]
4. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
[TBL] [Abstract][Full Text] [Related]
5. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
6. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.
Kisanga ER; Mellgren G; Lien EA
Anticancer Res; 2005; 25(6C):4487-92. PubMed ID: 16334131
[TBL] [Abstract][Full Text] [Related]
7. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Gjerde J; Gandini S; Guerrieri-Gonzaga A; Haugan Moi LL; Aristarco V; Mellgren G; Decensi A; Lien EA
Breast Cancer Res Treat; 2012 Jul; 134(2):693-700. PubMed ID: 22562123
[TBL] [Abstract][Full Text] [Related]
8. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Kisanga ER; Gjerde J; Guerrieri-Gonzaga A; Pigatto F; Pesci-Feltri A; Robertson C; Serrano D; Pelosi G; Decensi A; Lien EA
Clin Cancer Res; 2004 Apr; 10(7):2336-43. PubMed ID: 15073109
[TBL] [Abstract][Full Text] [Related]
10. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
Poon GK; Walter B; Lønning PE; Horton MN; McCague R
Drug Metab Dispos; 1995 Mar; 23(3):377-82. PubMed ID: 7628304
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
12. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
13. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
J Steroid Biochem; 1987 May; 26(5):547-55. PubMed ID: 3586671
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
[TBL] [Abstract][Full Text] [Related]
15. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
Lien EA; Anker G; Lønning PE; Solheim E; Ueland PM
Cancer Res; 1990 Sep; 50(18):5851-7. PubMed ID: 2393854
[TBL] [Abstract][Full Text] [Related]
16. Age-related difference in tamoxifen disposition.
Peyrade F; Frenay M; Etienne MC; Ruch F; Guillemare C; François E; Namer M; Ferrero JM; Milano G
Clin Pharmacol Ther; 1996 Apr; 59(4):401-10. PubMed ID: 8612384
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
18. Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation.
Brown RR; Bain R; Jordan VC
J Chromatogr; 1983 Feb; 272(2):351-8. PubMed ID: 6833432
[TBL] [Abstract][Full Text] [Related]
19. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography.
Lien EA; Ueland PM; Solheim E; Kvinnsland S
Clin Chem; 1987 Sep; 33(9):1608-14. PubMed ID: 3621560
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
